Tesamorelin
Overview
Tesamorelin, a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), was developed to specifically target and stimulate the release of growth hormone (GH) from the pituitary gland. Discovered and developed by Theratechnologies, a Canadian biopharmaceutical company, Tesamorelin was approved by the FDA in 2010 under the brand name Egrifta.
The primary function of Tesamorelin is to mimic the action of natural GHRH. By binding to GHRH receptors in the pituitary gland, it triggers the release of GH in a pulsatile fashion, mirroring the body's natural GH secretion pattern. This mechanism is particularly beneficial because it stimulates GH production without disrupting the normal regulation of the hormone, thus maintaining physiological balance.
Clinical trials have predominantly focused on Tesamorelin's efficacy in reducing visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat distribution. Studies have demonstrated significant reductions in VAT, along with improvements in related metabolic parameters. The drug's ability to decrease VAT, a risk factor for cardiovascular diseases, without significantly altering subcutaneous fat makes it a valuable treatment for lipodystrophy in HIV patients.
In terms of athletic performance, while Tesamorelin does increase GH levels, which can potentially enhance muscle mass and recovery, its use in this context is not supported by clinical evidence and is not recognized by health authorities for such purposes. The World Anti-Doping Agency (WADA) prohibits its use in competitive sports due to its GH-stimulating effects.
Overall, Tesamorelin represents a targeted approach to treating conditions associated with GH deficiency or abnormal fat distribution, particularly in the context of HIV-related lipodystrophy. However, its application in other areas, including athletic performance enhancement, is subject to ethical, legal, and medical constraints.
Dosage
To determine the dosage for Tesamorelin of 1000 mcg per day using a 6 mg vial reconstituted with 2 mL of bacteriostatic water, and assuming the use of a 0.5 mL, 50-unit insulin syringe, let's go through the necessary calculations:
Concentration Calculation:
6 mg of Tesamorelin is reconstituted in 2 mL of water.
Since 1 mg = 1000 mcg, the total amount is 6000 mcg.
The concentration is 6000 mcg / 2 mL = 3000 mcg/mL.
Dosage Calculation for 1000 mcg:
Volume in mL for a 1000 mcg dose: 1000 mcg3000 mcg/mL=0.33 mL3000 mcg/mL1000 mcg=0.33 mL.
Syringe Measurement:
A 0.5 mL syringe marked in 50 units equates to 0.01 mL per unit.
For 0.33 mL: 0.33 mL×100 units/mL=33 units0.33 mL×100 units/mL=33 units.
Therefore, for a daily dose of 1000 mcg of Tesamorelin from your prepared solution, you would draw up to the 33-unit mark on a 0.5 mL, 50-unit insulin syringe.
Tesamorelin is often stacked with Ipamoralin due to their synergistic effects. Tesamorelin also needs to be taken on an empty stomach as fats and carbohydrates negatively impact efficacy, so athletic performance researchers will often take a dose before bed (as growth hormone is primarily released during sleep), or they will take directly before or after an intense workout. It's important to follow this schedule and dosing closely and consult a healthcare provider with side-effects
For further details and specific guidance, it's recommended to consult healthcare professionals and refer to the full prescribing information from the manufacturer.
As always, this calculation is for informational purposes only, and actual medication dosing should be overseen by a healthcare professional.
Buy Tesamorelin/Ipamorelin Blend from Sigma Compounds.
Risks
Tesamorelin, used primarily for its effects on reducing visceral fat in HIV patients with lipodystrophy, has both short-term side effects and potential long-term risks. Understanding these is crucial for anyone considering or currently undergoing treatment with Tesamorelin.
Short-term Side Effects
These are effects that may occur soon after starting the medication and are typically reversible upon cessation of treatment:
Injection Site Reactions: Redness, itching, swelling, or irritation at the site of injection.
Muscle Aches and Pains: Some patients report discomfort or pain in the muscles.
Joint Pain: Joint discomfort or pain can occur.
Nausea and Vomiting: Gastrointestinal issues like nausea or vomiting might be experienced.
Night Sweats: Some individuals experience sweating excessively during the night.
Hyperglycemia: Elevated blood sugar levels, which are a concern, particularly for individuals with diabetes or pre-diabetes.
Palpitations: Some patients report feeling their heart beating hard, fast, or irregularly.
Long-term Risks
Long-term risks are associated with extended use of the medication and may have lasting impacts:
Potential Increase in Cancer Risk: Due to Tesamorelin’s mechanism of increasing growth hormone, there is a theoretical risk that it could stimulate the growth of certain cancers, though this has not been conclusively proven.
Cardiovascular Health: While Tesamorelin reduces visceral fat, which is a risk factor for cardiovascular disease, its long-term impact on heart health is not fully known.
Glucose Metabolism: Long-term effects on insulin sensitivity and risk of diabetes need to be monitored, especially given the hyperglycemia seen as a side effect.
Hormonal Imbalance: Extended use could potentially impact other hormonal systems due to its effect on growth hormone levels.
Use in Athletic Performance
While there is interest in Tesamorelin for athletic performance due to its growth hormone-releasing properties, such use is considered off-label and is not supported by clinical studies. The long-term risks, especially in healthy individuals using it for performance enhancement, are largely unknown.
In conclusion, while Tesamorelin has shown efficacy in reducing visceral fat in HIV-associated lipodystrophy, both its short-term side effects and long-term risks should be carefully considered and monitored under the guidance of a healthcare professional. The use of Tesamorelin, especially for non-approved purposes like athletic performance enhancement, should be approached with caution.